Eric Verdin

Verdin has articulated a durable and concrete geroscience vision centered on translating aging biology into personalized gerotherapeutics, biomarkers, clinical validation, and scalable interventions to extend healthy lifespan. The evidence shows ambition and specificity, while also preserving scientific caution around trials, dosing, safety, and variability. This is strong field-leadership evidence, though not quite maximal because much of it appears in coauthored academic or institutional contexts rather than a singular public manifesto explicitly claiming an end to aging.

Eric Verdin has field-defining scientific impact by the rubric's primary signal: OpenAlex reports an h-index of 133, 73,392 total citations, and multiple highly cited works in aging-relevant mechanisms including inflammation, NAD+ biology, sirtuins, mitochondrial metabolism, acetylation, and beta-hydroxybutyrate. The citation profile shows broad and sustained influence beyond publication volume, with several works exceeding 1,000 citations. Recent primary publications also show continued agenda-setting involvement in translational geroscience and biomarkers of aging, though the evidence does not show clinical trials directly led by him.

The dimension is applicable because Verdin leads a major longevity-focused research institute, but the provided evidence contains no disclosed personal investments, donations, fund allocations, or quantified capital deployment. His President/CEO role at the Buck Institute suggests institution-building responsibility in longevity, but without evidence of capital personally deployed or resources he directly allocated, the score must remain low.

Strategic taste is applicable because Verdin is linked to company formation and ecosystem roles, but the provided evidence does not show a clear investment or company-building thesis, timing, contrarian rationale, stage preference, or counterfactual importance. His scientific and institutional focus in aging biology suggests broad field coherence, but the evidence is too thin to credit strong strategic judgment beyond modest participation in longevity translation.

Evidence supports some field-creation activity: Verdin is credited with founding three longevity-related companies and is associated with The Academy of Health & Lifespan Research, which appears aimed at advancing geroscience as a field. However, the company-founding evidence lacks detailed independent corroboration here, all listed companies are marked inactive, and the Academy source shows affiliation/authorship rather than clearly proving he created the organization or program.

The dimension applies, but the provided evidence contains almost no direct indicators of public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or self-experimentation. Verdin is clearly a prominent geroscientist and institutional leader in aging research, but prominence and scientific output alone do not establish bravery/conviction under this rubric.

Eric Verdin shows substantial second-order leverage through founding three therapeutics companies, very high field citation reach, and participation in large cross-institutional consensus and translational longevity publications. The evidence supports broad scientific legitimacy, collaborators, and follow-on translational projects, but does not directly document capital attracted, policy influence, trainee/founder lineage, or investment/donation leverage.